For a study, researchers sought to talk about recently found mechanisms of action of several bacterial vaccinations that may explain their therapeutic effectiveness in the prevention of recurrent wheeze & asthma exacerbations in newborns & early children.

It had been demonstrated that innate immune cells are protected against a wide range of infections for a relatively long time thanks to trained immunity. There are certain bacterial vaccinations that induce trained immunity. In addition to their primary bacterial antigens, trained immunity-based vaccines (TIbV) of bacterial origin are able to elicit nonspecific reactions to a range of diseases, including respiratory viruses. Clinical evidence ranging from epidemiological studies to well-planned randomized clinical trials showed that TIbV formulations containing bacteria protect against viral respiratory tract infections, such as those linked to recurrent wheezing or asthma flare-ups in children. For these vaccinations to be effective against respiratory infections, mucosal administration may be crucial.

Through a process mediated by trained immunity, mucosal bacterial immunotherapy, including certain TIbV, gave protection against a wide range of pathogens, such as viruses. These molecular effects are reflected in clinical research on the use of these medications to treat recurrent wheeze. The results offered up a new field for the creation of novel treatments for the illness.